October 1, 2026

Autolomous is proud to support CTMC as it advances a partner tumor-infiltrating lymphocyte (TIL) program into pivotal-stage manufacturing.As part of CTMC’s investment in the digital infrastructure required for increased volumes of patient-specific manufacturing, CTMC has implemented a tailored digital chain-of-identity and chain-of-custody (COI/COC) solution developed in collaboration with Autolomous and powered by the autoloMATE® platform.

The solution provides robust end-to-end traceability across patient-specific manufacturing operations, helping CTMC strengthen the consistency, compliance and operational readiness required as advanced therapy programs progress toward commercialization.

This milestone demonstrates how purpose-built digital infrastructure can support the transition from clinical development to registration-enabling and commercial-scale manufacturing.

Read the full CTMC press release on Business Wire → Link